B. Riley Analysts Boost Earnings Estimates for CNTA

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Investment analysts at B. Riley raised their Q4 2025 EPS estimates for Centessa Pharmaceuticals in a research note issued on Monday, December 1st. B. Riley analyst M. Mamtani now forecasts that the company will earn ($0.38) per share for the quarter, up from their previous forecast of ($0.45). B. Riley has a “Buy” rating and a $42.00 price target on the stock. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. B. Riley also issued estimates for Centessa Pharmaceuticals’ FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($2.06) EPS.

Several other research analysts have also issued reports on the company. Chardan Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Wells Fargo & Company upped their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Truist Financial set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $35.50.

Centessa Pharmaceuticals Price Performance

Centessa Pharmaceuticals stock opened at $29.08 on Wednesday. The business has a 50 day simple moving average of $24.83 and a 200 day simple moving average of $18.96. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. The company has a market capitalization of $3.91 billion, a PE ratio of -15.89 and a beta of 1.55. Centessa Pharmaceuticals has a one year low of $9.60 and a one year high of $29.99.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. TCG Crossover Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 8.5% during the third quarter. TCG Crossover Management LLC now owns 3,136,480 shares of the company’s stock valued at $76,060,000 after acquiring an additional 245,664 shares during the period. Verition Fund Management LLC bought a new stake in Centessa Pharmaceuticals during the 3rd quarter worth about $2,772,000. Jain Global LLC bought a new stake in Centessa Pharmaceuticals during the 3rd quarter worth about $5,868,000. HighVista Strategies LLC lifted its position in Centessa Pharmaceuticals by 55.6% during the 3rd quarter. HighVista Strategies LLC now owns 63,301 shares of the company’s stock valued at $1,535,000 after purchasing an additional 22,617 shares during the period. Finally, Fred Alger Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 53.8% in the 3rd quarter. Fred Alger Management LLC now owns 190,360 shares of the company’s stock valued at $4,616,000 after purchasing an additional 66,604 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CTO Tia L. Bush sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the transaction, the chief technology officer directly owned 121,503 shares in the company, valued at approximately $3,159,078. This represents a 24.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Iqbal J. Hussain sold 20,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total transaction of $400,200.00. Following the sale, the general counsel directly owned 105,386 shares in the company, valued at $2,108,773.86. This trade represents a 15.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 179,964 shares of company stock valued at $4,106,481. Insiders own 7.09% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.